Cerebrospinal fluid (CSF) biomarkers and neuroimaging, particularly targeting amyloid and tau pathology, have advanced the diagnosis of Alzheimer's disease (AD), particularly towards its early stages. Here, MAPT is linked to early-onset autosomal dominant Alzheimer disease.